Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma

BACKGROUND: Thymic epithelial tumors are PD-L1–expressing tumors of thymic epithelial origin characterized by varying degrees of lymphocytic infiltration and a predisposition towards development of paraneoplastic autoimmunity. PD-1–targeting antibodies have been evaluated, largely in patients with t...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:J Immunother Cancer
Main Authors: Rajan, Arun, Heery, Christopher R., Thomas, Anish, Mammen, Andrew L., Perry, Susan, O’Sullivan Coyne, Geraldine, Guha, Udayan, Berman, Arlene, Szabo, Eva, Madan, Ravi A., Ballester, Leomar Y., Pittaluga, Stefania, Donahue, Renee N., Tsai, Yo-Ting, Lepone, Lauren M., Chin, Kevin, Ginty, Fiona, Sood, Anup, Hewitt, Stephen M., Schlom, Jeffrey, Hassan, Raffit, Gulley, James L.
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2019
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6805423/
https://ncbi.nlm.nih.gov/pubmed/31639039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0723-9
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים